Fibrillary glomerulonephritis: lessons from anti-CD20 therapy and repeat biopsy
The present study confirms that FGN is primarily a B-cell-driven disease and provides evidence that FGN can be effectively managed by achieving a profound depletion of CD20+ B lymphocytes; the disease is highly progressive and probably requires prolonged maintenance treatment; and, last, early diagnosis is critical for long-term outcome because a significant glomerular sclerosis at the time of the first biopsy precludes the possibility of reversing or stabilizing the course of the disease.
Authors
- Dario Roccatello (ORCID: https://orcid.org/0000-0002-4419-6813)
- Savino Sciascia (ORCID: https://orcid.org/0000-0003-1266-9441)
- Simone Cortazzi
- Emanuele De Simone (ORCID: https://orcid.org/0000-0002-0760-5737)
- Antonella Barreca (ORCID: https://orcid.org/0000-0003-3566-1995)
- Giulio Del Vecchio
- Roberta Fenoglio (ORCID: https://orcid.org/0000-0001-8019-5749)
- Rossana Giachino
Institutions
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Ospedale San Giovanni Bosco (IT)
- University of Turin (IT)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/ndt/gfaf109
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00